Financial Performance Overview

Hanol Bio Pharma has announced a 6% year-over-year increase in sales for the first quarter of 2025, reaching ₩36.1 billion.While the company experienced operating and net profit deficits of ₩390 million and ₩210 million respectively, this was attributed to increased costs associated with unfavorable exchange rates.

Key Growth drivers: Pharmaceuticals and Biotechnology

Pharmaceutical sales were a meaningful contributor to the company’s growth, increasing by 11% to ₩31.8 billion. Notably, the probiotic product Bio Top and the hair loss treatment Hairgro experienced substantial growth of 28% and 38% respectively. The biotechnology division also performed strongly,achieving sales of ₩5.1 billion in the first quarter, solidifying its market presence.

Market Position of Hairgro

According to data from UBIST, a pharmaceutical market research firm, hairgro secured the second-largest market share in the hair loss treatment category during the first quarter of 2025. This demonstrates the product’s strong competitive standing and consumer acceptance.

Advancements in New Drug Development

Hanol Bio Pharma is making significant strides in new drug development. Bato Klimab received rare pharmaceutical designation for thyroid Eye Disease (TED) in Japan in February. Furthermore, Phase III clinical trials for severe work, developed by Immu Norach, have shown promising results, including a reduction in self-antibodies and a positive treatment response rate. Immu Norach is actively pursuing clinical trials for Bato Klimab.

“It is an important time to confirm the possibility of a positive change for patients in the actual medical field in the first quarter. We will continue to present new standards for treatment through differentiated new drug development and strengthen our competitiveness in the global market.”

chung seung-won, CEO of Hanol Bio Pharma